Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel Buys 1,000 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average cost of $24.50 per share, for a total transaction of $24,500.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $122,500. This trade represents a 25.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Anja Manuel also recently made the following trade(s):

• On Tuesday, November 12th, Anja Manuel purchased 4,000 shares of Hims & Hers Health stock. The stock was acquired at an average cost of $26.94 per share, for a total transaction of $107,760.00.

Hims & Hers Health Stock Down 24.5 %

HIMS stock traded down $6.76 during mid-day trading on Thursday, hitting $20.85. 62,625,345 shares of the company were exchanged, compared to its average volume of 9,152,479. The firm has a market capitalization of $4.48 billion, a P/E ratio of 49.34 and a beta of 1.06. Hims & Hers Health, Inc. has a 12-month low of $7.40 and a 12-month high of $30.44. The business has a fifty day simple moving average of $19.51 and a 200-day simple moving average of $18.77.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business’s quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) earnings per share. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently modified their holdings of HIMS. Robeco Institutional Asset Management B.V. purchased a new position in Hims & Hers Health in the third quarter valued at $604,000. Carnegie Investment Counsel purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $5,531,000. International Assets Investment Management LLC purchased a new stake in shares of Hims & Hers Health during the third quarter worth approximately $6,790,000. Versor Investments LP purchased a new position in Hims & Hers Health in the third quarter worth approximately $634,000. Finally, Sei Investments Co. grew its holdings in Hims & Hers Health by 206.9% during the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after acquiring an additional 37,890 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Truist Financial lifted their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Finally, TD Cowen boosted their target price on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $21.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.